<DOC>
	<DOCNO>NCT01187563</DOCNO>
	<brief_summary>This open-label , uncontrolled , observational study patient rheumatoid arthritis ( RA ) receive tocilizumab concomitantly methotrexate part standard care .</brief_summary>
	<brief_title>A Study Tocilizumab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This single arm , open label study evaluate safety pharmacodynamic profile tocilizumab RA patient . Participating patient among tocilizumab indicate schedule receive tocilizumab part normal care , full compliance FDA-approved prescribing information . Study assessment consist clinical evaluation laboratory test conduct conjunction first three monthly intravenous infusion tocilizumab . These assessment design provide good understanding pharmacodynamic effect mechanistic action tocilizumab help guide clinical development therapeutic agent RA . A total 15 patient expect participate approximately 10 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>â‰¥ 18 year age Moderately severely active rheumatoid arthritis Inadequate response previous treatment antiTNF agent Receiving methotrexate least 12 wks study Previous treatment tocilizumab Previous treatment IL6 receptor inhibitor Treatment corticosteroid ( oral prednisone &gt; 10 mg/day equivalent ) within 4 wks Conditions note tocilizumab prescribe information</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Rheumatoid arthritis , tocilizumab</keyword>
</DOC>